CPD Activities

Procalcitonin in the management of severe bacterial sepsis


Procalcitonin in the management of severe bacterial sepsis


Starting on :06:00 PM 03 December, 2015 Venue:PanAfric
Ending on :09:00 PM 03 December, 2015 Max Credits:10
Moderator:No Activity Moderator Activity Cost: Free Order

Presenters

1. Dr. Becze Zsolt
Thermo Scientific are the Lead manufacturers of Clinical diagnostics products and Meditec represents their branch for bench top clinical chemistry analyzers and Procalcitonin POC solutions.

2. Mr. Roshanali Jin
Thermo Scientific are the Lead manufacturers of Clinical diagnostics products and Meditec represents their branch for bench top clinical chemistry analyzers and Procalcitonin POC solutions.

Description

The systemic inflammatory response is based on the innate and adaptive immune response and within them on the pro and anti-inflammatory processes, which are simultaneously built up, short-lived and self-limited.   The rules of procalcitonin (PCT) usage in septic patients are based on PCT measurement at the admission, followed by daily measurements to detect the maximum PCT value and beyond the PCT value changes which declines according to the therapy appropriateness. The use of PCT in sepsis after previous sepsis or chronic critically ill patients follows the same rules as in “normal” but the maximum PCT value reached is lower, despite this the smaller PCT values should be taken more seriously since they are generated by a particular exhausted immune and organ response. The use of PCT does not differ from non-immunosuppressed one, but the initiation time of an appropriate treatment is shorter in this subpopulation.


Objectives

The goal of the anti-inflammatory process is to restore the immune homeostasis and prevent systemic inflammation and organ dysfunction, but a pathologically exaggerated and prolonged anti-inflammatory phenotype is harmful with a higher nosocomial infection rate. 





Online Register